

Measles and rubella elimination country profile

United Kingdom of Great Britain and Northern Ireland

Measles elimination status

2015 Interrupted
2016 eliminated



Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

National plan of action

Does the country have a national plan of action?
In the making
Is it updated? NA



Source: Measles and rubella elimination Annual Status Update report, 2016
ND= Data not available


Measles and rubella immunization schedule, 2016

	Vaccine	Schedule	Year of introduction	
MCV1	MMR	12 months	MCV2	1996
MCV2	MMR	3 years and 4 months	RCV	1970
Measles vaccination in school				Yes

Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)
MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vaccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine

Definition used for an outbreak

Clusters (2 < cases) are defined on the basis of known contact between cases or if attendance at the same event or the same institution occurred during the appropriate period




Source: Measles and rubella elimination Annual Status Update report, 2016



Rubella elimination status

2015 eliminated
2016 eliminated




Source: European Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report: www.euro.who.int/6thRVC

Demographic information, 2016

Total population	65 111 143
< 1 year old	809 588
< 5 years old	3 987 894


Source: World Population Prospects: The 2015 Revision, New York, United Nations

Measles and rubella cases and immunization coverage, 2007–2016



Source: Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/)
MCV1 = first dose of measles-containing vaccine
MCV2 = second dose of measles-containing vaccine

Confirmed measles cases by month of onset, 2012–2016




Source: CISID2 2016

Measles and rubella elimination country profile


United Kingdom of Great Britain and Northern Ireland

Measles cases by first subnational level, 2016



Source: Measles and rubella elimination Annual Status Update report, 2016


Measles genotypes by first subnational level, 2016



Source: MeaNS 2016

Note: The dots in the maps are placed randomly within the administrative regions
Map disclaimer: The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Measles cases by age group and vaccination status, 2016




Source: Measles and rubella elimination Annual Status Update report, 2016
 (No age group and vaccination status data submitted)

Sources of infection, 2016

	Measles	Rubella
Imported	39	1
Import-related	669	1
Unknown/ Not reported	0	0
Endemic	0	0

Source: Measles and rubella elimination Annual Status Update report, 2016

Information on CRS, 2016



Source: Measles and rubella elimination Annual Status Update report, 2016
 CRS = congenital rubella syndrome

Measles and rubella elimination country profile

United Kingdom of Great Britain and Northern Ireland

Measles incidence, epidemiologic and virologic characteristics, 2012-2016

	Suspected measles cases	Confirmed measles cases				Discarded as non-measles	Measles incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2012	ND	2 079	3	0	2 082	ND	32.2	B3,D4,D8,D9
2013	8 578	1 903	17	0	1 920	6 596	28.9	B3,D4,D8,D9,H1
2014	3 459	144	0	0	144	3 239	1.5	B3,D8,H1
2015	2 270	91	1	0	92	2 154	1.1	B3,D4,D8,H1
2016	3 627	594	52	62	708	2 923	10.4	B3, D4, D8

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Measles surveillance and laboratory performance indicators, 2012-2016

	Discarded non-measles rate	% 1st sub-national unit with > 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for measles	% positive for measles	Rate of viral detection	% WHO and proficient labs
2012	8.5	ND	111%	100%	ND	ND	ND	100%
2013	10.3	72%	>89%	100%	ND	ND	100%	100%
2014	3.8	50%	83.3%*	100%	2 562	5.6%	100%	100%
2015	3*	50%	70%*	100%	1 615*	5.6%*	100%	100%
2016	3.7*	66%	83%*	100%	2 624	23.2%	91%**	100%

Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory. *mean without Scotland. **data without NI

Rubella incidence, epidemiologic and virologic characteristics, 2012-2016

	Suspected rubella cases	Confirmed measles cases				Discarded as non-rubella	Rubella incidence	Genotypes detected
		Laboratory	Epi-linked	Clinically	Total			
2012	ND	70	0	0	70	ND	0.8	ND
2013	1 083	13	0	0	13	1 041	0.1	ND
2014	1 030	2	1	0	3	1 027	0	1G
2015	740	3	0	0	3	725	0	2B
2016	598	2	0	0	2	596	0	1G,2B

Source: Measles and rubella elimination Annual Status Update report, 2012-2016
Incidence calculated per 1 million population
ND = Data not available; NA= Not applicable

Rubella surveillance and laboratory performance indicators, 2012-2016

	Discarded non-rubella rate	% 1st sub-national unit with > 2 discarded cases	% cases with adequate laboratory investigation	% origin of infection known	# specimen tested for rubella	% positive for rubella	Rate of viral detection	% WHO and proficient labs
2012	2.4	ND	162%	100%	ND	ND	ND	100%
2013	1.6	<80%	124%	100%	ND	ND	NA	100%
2014	1.3	0%	91%	100%	804	0%	NA	100%
2015	2.2*	25%	66.3%*	100%	534*	0.6%*	33%	100%
2016	3.2*	41%	66.5%*	100%	369	2.7%	0	100%

Source: ASU 2012-2016, RubeNS 2012-2016 and laboratory accreditation results 2012-2016
ND = Data not available; NA= Not applicable
A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory. *mean without Scotland. **data without NI

RVC comments, based on 2016 reporting

The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in the United Kingdom of Great Britain and Northern Ireland in 2016. The RVC confirmed that rubella elimination has been sustained and, considering its conclusions about the interrupted status of measles transmission in the country in 2014 and 2015, the RVC is pleased to declare that the United Kingdom of Great Britain and Northern Ireland has achieved elimination of measles. While commending this achievement, the RVC would appreciate receiving information on steps being taken to access case-based measles and rubella surveillance data from Scotland, which would allow for development of standard surveillance indicators for the United Kingdom as a whole. The RVC invites the National Verification Committee (NVC) and national health authorities to implement modifications that will lead to submission of comprehensive data in the ASU in future. The RVC anticipates that the national public health system will maintain high-quality surveillance and high routine immunization coverage.

Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)

Surveillance performance indicators and targets

- Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population
- % cases with adequate laboratory investigation: \geq 80%
- % origin of infection known: \geq 80%
- Rate of viral detection: \geq 80%